Quantitative epstein barr virus PCR rapid assay 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
US2003175684 A1 2003-09-18 [US20030175684]US6790952 B2 2004-09-14 [US6790952] / 2003-09-182004-09-14
申请号/申请日
2002US-10074620 / 2002-02-13
发明人
GROEN PAMELA A;WITTE DAVID P;
申请人
CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION;
主分类号
IPC分类号
C12Q-001/70
摘要
(US6790952) The present invention provides novel compositions comprising Epstein-Barr virus-specific oligonucleotides that are useful as primers to amplify particular regions of the genome during enzymatic nucleic acid amplification.  The invention also provides a rapid, sensitive and specific method for the detection and quantitation of the virus which may be present in a clinical specimen, using the virus-specific primers and enzymatic nucleic acid amplification; hybridization of amplified target sequences, if present, with one or more Epstein-Barr virus-specific oligonucleotide probes which are labeled with a detectable moiety; and detection of the detectable moiety of labeled oligonucleotide probe hybridized to amplified target sequences of Epstein-Barr virus DNA.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2001US-60268439 2001-02-13 2002US-10074620 2002-02-13
主权利要求
(US6790952) 1. An isolated and purified oligonucleotide primer pair for enzymatic amplification of Epstein-Barr virus DNA, consisting essentially of a pair of nucleic acid sequences which complement and specifically hybridize to a nucleic acid sequence of an Epstein-Barr virus under stringent conditions, which encodes a conserved EBNA2 region of the Epstein-Barr virus genome, wherein the pair of nucleic acid sequences is at least 95% homologous to sequences of SEQ ID NO: 1 and SEQ ID NO: 2, respectively. What is claimed is: 2.  An isolated and purified oligonucleotide primer pair for enzymatic amplification of Epstein-Barr virus DNA, consisting essentially of a pair of nucleic acid sequences which complement and specifically hybridize to a chromosomal gene of an Epstein-Barr virus under stringent conditions, and which encodes a conserved EBNA2 region of the Epstein-Barr virus genome, wherein the pair of nucleic acid sequences is selected from the group consisting of (a) the oligonucleotide pair of SEQ ID NO: 1 and SEQ ID NO:2, and (b) a primer pair, which differs from SEQ ID NO: 1 and SEQ ID NO: 2 by a one base change or substitution therein, and (d). 3. A method of detecting the presence of Epstein Barr virus DNA in a sample comprising:     a) contacting the sample with oligonucleotide primer pair of SEQ ID NO. 1 and SEQ ID NO: 2 under suitable conditions permitting hybridization of the oligonucleotides to the Epstein Barr virus DNA, b) enzymatically amplifying a region of the Epstein Barr virus DNA using the oligonucleotide pair SEQ ID NO: 1 and SEQ ID NO: 2 to form nucleic acid amplification products, c) contacting the amplified Epstein Barr virus DNA sequences from step (b), if present, with hybridization probes comprising the oligonucleotide pair of SEQ.  ID. NO. 3 and SEQ. ID. NO. 4 or the oligonucleotide pair of SEQ.  ID. NO. 7 and SEQ. ID. NO. 8, labeled with a detectable moiety under suitable conditions permitting hybridization of the labeled oligonucleotide probe to amplified Epstein Barr virus DNA sequences, and d) detecting the presence of amplified Epstein Barr virus DNA sequences by detecting the detectable moiety of the labeled oligonucleotide probe hybridized to the amplified Epstein Barr virus DNA sequences. 4. The method of claim 3, wherein the sample is treated to release nucleic acid molecules from cells in the sample prior to step (a). 5. The method of claim 3, wherein the presence of the amplified Epstein Barr virus DNA sequences hybridized to labeled oligonucleotide probe correlates to the presence of Epstein Barr virus in the sample. 6. The method of claim 5, wherein the amplified DNA sequences are from the EBNA2 region of the Epstein Barr virus genome. 7. The method of claim 5, additionally comprising adding an internal standard for accessing relative amounts of Epstein Barr virus after amplification. 8. The method of claim 5, wherein presence of the amplified Epstein Barr virus DNA sequences hybridized to labeled oligonucleotide probe is correlated to the presence of Epstein Barr virus in the sample by comparing the amount of amplification product to the quantity of amplification products formed from known internal standards. 9. The method of claim 5, wherein the amplification is performed by cyclic polymerase-mediated reaction. 10. The method of claim 9, wherein the cyclic polymerase-mediated reaction is an enzymatic assay selected from the group consisting of PCR, LCR, SDA, Qbeta RA, 3SR, and NASBA. 11. The method of claim 10, wherein the polymerase is selected from the group consisting of thermostable polymerase, E. coli DNA pol I, Klenow fragment, and T7 DNA polymerase. 12. The method of claim 11, wherein the PCR is a thermocyclic reaction. 13. The method of claim 5, wherein the detectable moiety is selected from the group consisting of a digoxigenin-dUTP, biotin, calorimetric, fluorescent, chemiluminescent, electrochemiluminescent signal and a radioactive component. 14. The method of claim 5, wherein the detectable moiety is a fluorescent component generating a fluorescent signal. 15. The method of claim 11, the amount of amplification product is determined simultaneously with respect to the PCR amplification step. 16. A method of selecting an appropriate dosage or type of antiviral agent for treating an infection caused by Epstein Barr virus comprising the steps of:     a) obtaining a sample from a patient to be treated;    b) preparing the sample for PCR amplification;    c) adding PCR reagents to the prepared sample, including one primer pair SEQ ID NO: 1 and SEQ ID NO: 2 and complementary sequences thereof;    d) maintaining the prepared sample of step c under conditions suitable for amplification;    e) adding at least one probe labeled with a detectable moiety corresponding to the primer pair, selected from the group consisting of the oligonucleotide pair of SEQ.  ID. NO. 3 and SEQ. ID. NO. 4, the oligonucleotide pair of SEQ.  ID. NO. 7 and SEQ. ID. NO. 8, and complementary sequences thereof, under suitable conditions permitting hybridization;    f) measuring quantitatively one or more of the Epstein Barr virus species contained in the sample;    and vii) selecting the type or adjusting the dosage of the antiviral agent based on the quantitative measurement. 17. The method of claim 16 additionally comprising adding to step c) an internal standard for accessing relative amounts of Epstein Barr virus after amplification. 18. The method of claim 17, wherein the PCR reagents comprise a polymerase selected from the group consisting of thermostable polymerase, E. coli DNA pol I, Klenow fragment, and T7 DNA polymerase. 19. The method of claim 18, wherein the detectable moiety is selected from the group consisting of a digoxigenin-dUTP, biotin, calorimetric, fluorescent, chemiluminescent, electrochemiluminescent signal and a radioactive component. 20. The method of claim 10, further comprising a separation step wherein the amplified product is isolated. 21. A method for the simultaneous amplification and detection of Epstein Barr Virus DNA in a sample comprising:     a) processing the sample to produce denatured opposing strands of DNA;    b) simultaneously subjecting the denatured opposing strands of DNA to polymerase chain reaction in the presence of:     i) an aqueous solution buffered to a pH of about 6 to about 9;    and ii) first and second primers which are specific to and hybridizable with the denatured opposing strands of DNA, wherein the sequences of the first and second primers are SEQ ID NO: 1 and SEQ ID NO: 2 and c) simultaneously detecting the amplified DNA using hybridization probes comprising the oligonucleotide pair of SEQ.  ID. NO. 3 and SEQ. ID. NO. 4 or the oligonucleotide pair of SEQ.  ID. NO. 7 and SEQ. ID. NO. 8. 22. The method of claim 21 wherein the hybridization probe further comprises a detectable moiety selected from the group consisting of a chemiluminescent component, a fluorescent component, and a radioactive component. 23. A diagnostic test kit for detection of Epstein Barr virus comprising:     (a) at least one oligonucleotide primer pair SEQ ID NO: 1 and SEQ ID NO: 2 and both the oligonucleotide pair and (b) at least one oligonucleotide probe labeled with a detectable moiety selected from the group consisting SEQ.  ID. NO. 3, SEQ. ID. NO. 4, SEQ. ID. NO. 7 and SEQ. ID. NO. 8. 24. The diagnostic test kit of claim 23, further comprising at least one additional reagent selected from the group consisting of a lysing buffer for lysing cells contained in the specimen;  enzyme amplification reaction components dNTPs, reaction buffer, and amplifying enzyme;  and a combination thereof. 25. The diagnostic kit of claim 23, wherein the hybridization probe further comprises a detectable moiety selected from the group consisting of a chemiluminescent component, a fluorescent component, and a radioactive component.
法律状态
(US6790952) LEGAL DETAILS FOR US2003175684  Actual or expected expiration date=2016-10-10    Legal state=DEAD    Status=LAPSED     Event publication date=2002-02-13  Event code=US/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=US US10074620  Application date=2002-02-13  Standardized application number=2002US-10074620     Event publication date=2002-02-13  Event code=US/EXMR  Event type=Administrative notifications  USPTO Examiner Name Primary Examiner: LI, BAO Q    Event publication date=2002-02-13  Event code=US/ART  Event type=Administrative notifications  USPTO Art Group  ART=1648     Event publication date=2002-02-13  Event code=US/SMALL  Event type=Administrative notifications  Appl Has Filed a Verified Statement of Micro to Small Entity Status Business Entity Status: SMALL    Event publication date=2002-02-13  Event code=US/AIA  Event type=Administrative notifications  First Inventor File Indicated:  AIA=No     Event publication date=2002-02-13  Event code=US/CUST  Event type=Examination events  Attorney/Agent Customer Number Customer Nbr: 26874    Event publication date=2002-02-13  Event code=US/AS  Event type=Change of name or address  Event type=Reassignment  Assignment Owner: CINCINNATI CHILDREN'S HOSPITAL RESEARCH FOUNDATION  Effective date of the event=2002-02-13  ASSIGNMENT OF ASSIGNORS INTEREST ASSIGNORS:WITTE, DAVID P. GROEN, PAMELA A. REEL/FRAME:012612/0024     Event publication date=2002-07-11  Event code=US/DOCK  Event indicator=Pos  Event type=Examination events  Case Docketed to Examiner    Event publication date=2002-11-25  Event code=US/IDS  Event type=Examination events  Event type=OAI  Information Disclosure Statement Filed    Event publication date=2003-04-07  Event code=US/RESTREQ  Event type=Examination events  Event type=Corrections  Event type=OAO  Restriction/Election Requirement    Event publication date=2003-05-08  Event code=US/ELC  Event type=Examination events  Event type=OAI  Response to Election / Restriction Filed    Event publication date=2003-07-07  Event code=US/RESTREQ  Event type=Examination events  Event type=Corrections  Event type=OAO  Restriction/Election Requirement    Event publication date=2003-07-31  Event code=US/ELC  Event type=Examination events  Event type=OAI  Response to Election / Restriction Filed    Event publication date=2003-08-25  Event code=US/CTNF  Event type=Examination events  Event type=OA  Event type=OAO  Non-Final Rejection    Event publication date=2003-09-18  Event code=US/A1  Event type=Examination events  Application published  Publication country=US  Publication number=US2003175684  Publication stage Code=A1  Publication date=2003-09-18  Standardized publication number=US20030175684     Event publication date=2004-02-05  Event code=US/CTNFR  Event type=Examination events  Event type=OAI  Response after Non-Final Action    Event publication date=2004-02-05  Event code=US/136G  Event type=OAO  Request for Extension of Time - Granted    Event publication date=2004-05-03  Event code=US/DOCK  Event indicator=Pos  Event type=Examination events  Case Docketed to Examiner    Event publication date=2004-05-06  Event code=US/NOAM  Event indicator=Pos  Event type=Examination events  Event type=OAO  Mail Notice of Allowance    Event publication date=2004-08-16  Event code=US/APRDY  Event indicator=Pos  Event type=Examination events  Application Is Considered Ready for Issue    Event publication date=2004-08-26  Event code=US/ISSM  Event indicator=Pos  Event type=Examination events  Event type=OAO  Event type=Restitution or restoration  Issue Notification Mailed    Event publication date=2004-09-14  Event code=US/B2  Event indicator=Pos  Event type=Event indicating In Force  Granted patent as second publication  Publication country=US  Publication number=US6790952  Publication stage Code=B2  Publication date=2004-09-14  Standardized publication number=US6790952     Event publication date=2004-09-14  Event code=US/354  Event indicator=Pos  Event type=Extension of term of duration of protection  Patent term extended under  35 U.S.C 154(b) until/for Delays (A,B,C): 0  Overlap Delays: 0  Non Overlap Delays: 0   PTO Office Delays: 0  Applicant Delays: 73  Adjustment total:  Number of days of extension=0    Event publication date=2008-03-14  Event code=US/FPAY  Event indicator=Pos  Event type=Event indicating In Force  Event type=Payment or non-payment notifications  Fee payment recorded   Annual fees payment date=2008-03-14     Year of payment of annual fees=4     Event publication date=2012-03-14  Event code=US/FPAY  Event indicator=Pos  Event type=Event indicating In Force  Event type=Payment or non-payment notifications  Fee payment recorded   Annual fees payment date=2012-03-14     Year of payment of annual fees=8     Event publication date=2016-04-22  Event code=US/REMI  Event type=Administrative notifications  Maintenance fee reminder mailed    Event publication date=2016-09-14  Event code=US/LAPS  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Lapse for failure to pay maintenance fees    Event publication date=2016-09-14  Event code=US/FP  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Expired due to failure to pay maintenance fee  Effective date of the event=2016-09-14     Event publication date=2016-10-07  Event code=US/EXP  Event indicator=Neg  Event type=Event indicating Not In Force  Patent expired    Event publication date=2016-10-10  Event code=US/FP  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Expired due to failure to pay maintenance fee
专利类型码
A1B2
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部